Prescient Therapeutics Limited

PTX

AU000000PTX3

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 09:29:36 03/06/2024 am IST			5-day change	1st Jan Change
0.047 ^AUD	+4.44%		+4.44%	-24.19%

25/03	Transcript : Prescient Therapeutics Limited - Special Call
23/02	Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Prescient Therapeutics Limited Announces Retirement of Mr. Paul Hopper as Non-Executive Director

January 02, 2020 at 04:34 am IST

Prescient Therapeutics Limited announced retirement of Mr. Paul Hopper as Non-executive Director effective 2 January 2020 in order to pursue other business interests.

Latest news about Prescient Therapeutics Limited

Transcript : Prescient Therapeutics Limited - Special Call	25/03
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02	CI
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	28/11	MT
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/23/25	CI
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	15/23/15	CI
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	16/23/16	CI
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	09/23/09	MT
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	09/23/09	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24	CI
Transcript : Prescient Therapeutics Limited - Shareholder/Analyst Call	29/22/29
Prescient Therapeutics Sees Positive Results in PTX-100 Study	26/22/26	MT
Prescient Therapeutics Limited Announces PTX-100 Trial Update	25/22/25	CI
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	23/22/23	MT
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	23/22/23	CI
Transcript : Prescient Therapeutics Limited - Special Call	08/22/08
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	07/22/07	MT
Transcript : Prescient Therapeutics Limited - Special Call	07/22/07
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	07/22/07	CI
Prescient Therapeutics Launches $6 Million Share Purchase Plan	24/22/24	MT
Transcript : Prescient Therapeutics Limited - Special Call	23/22/23
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	18/22/18	CI
Prescient Therapeutics Enters Manufacturing Deal for CAR-T Therapy OmniCAR for Clinical Trials Ahead	16/22/16	MT
Prescient Therapeutics Secures Orphan Drug Designation in US for Lymphoma Drug; Shares Rally 19%	15/22/15	MT
Prescient Therapeutics Secures US Patent for OmniCAR Platform; Shares Rise 6%	05/22/05	MT

Chart Prescient Therapeutics Limited

Duration

Period

More charts

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRESCIENT THERAPEUTICS LIMITED	-24.19%	24.06M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B